CRBU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Caribou Biosciences Inc (CRBU) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline and hedge funds are showing interest, the technical indicators are weak, and the stock is currently in a downtrend. Additionally, no strong proprietary trading signals are present, and the financials show significant cash burn and negative net income. It would be prudent to wait for clearer signs of growth or stability before investing.
The MACD is negatively expanding, RSI is neutral at 39.15, and moving averages are converging, indicating no clear upward momentum. The stock is trading near its support level of 1.71, with resistance at 2.134. Overall, the technical indicators suggest a bearish or neutral trend.
Hedge funds are significantly increasing their positions, with a 1731.04% increase in buying over the last quarter.
The company reported strong Q4 revenue growth of 89.4% YoY, beating expectations.
Promising pipeline developments, including a Phase 3 trial for vispa-cel and dose expansion for CB-011.
The stock price has declined by 5% in the regular market and 1.17% in post-market trading.
Financials show a significant cash burn, with cash reserves dropping from $249.4M in 2024 to $142.8M in
No recent congress trading data or strong insider buying trends.
In Q4 2025, revenue increased by 89.4% YoY to $3.94M, beating expectations. However, the company reported a GAAP EPS of -$0.28 and a significant cash burn, with cash reserves decreasing to $142.8M. Net income remains negative, and EPS declined by 21.05% YoY in Q3 2025.
Analysts are optimistic about the company's long-term prospects, with Clear Street initiating coverage with a Buy rating and a $13 price target. BofA also maintains a Buy rating but lowered its price target from $8 to $6, citing broader concerns in the biotech sector despite positive catalysts.
